Zynteglo Is Cost Effective At $2.1M, ICER Proposes; Validation For Bluebird’s Pivot To US?

bluebird bio’s gene therapy for beta thalassemia, Zynteglo (betibeglogene autotemcel), would be cost effective at a price of $2.1m, especially if payments are spread over five years and based on outcomes, the Institute for Clinical and Economic Review (ICER) tentatively concludes in a draft evidence report released 13 April.

“Despite remaining uncertainties, the evidence suggests that beti-cel provides net health benefits to patient with [transfusion dependent thalassemia] and given the high annual costs of standard of care, traditional cost effectiveness modeling finds that this new treatment meets commonly accepted value thresholds at a cumulative price of $2